Google
BFRG Stock Price & Analysis — Bullfrog Ai Holdings, Inc. Common Stock (Healthcare >> Health Information Services)
BFRG FAQ
What is BFRG's ROE?
Bullfrog Ai Holdings, Inc. Common Stock reports a Return on Equity (ROE) of -124.29%.
What is BFRG's dividend yield?
Bullfrog Ai Holdings, Inc. Common Stock offers a dividend yield of 0.00%.
What is BFRG's Quality Score?
Our AI rates BFRG's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BFRG?
Our AI Timing Score for BFRG is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BFRG belong to?
Bullfrog Ai Holdings, Inc. Common Stock is classified under the Healthcare >> Health Information Services sector on the NASDAQ exchange
BFRG AI Analysis Summary
Our AI summary for BFRG: Bullfrog Ai Holdings, Inc. Common Stock (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of 0.00, ROE of -124.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.62
Price
0.00
(0.57%)
Day Change
|
|
|---|
BFRG, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
38% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.62 |
| PBV / Sector |
2.34 / 6.46
|
| Earning Per Share | -0.33 |
| PE / Sector |
N/A / 45.42
|
| PEG or PE/Growth / Sector |
N/A / -0.35
|
| Average 1M Daily Value |
0.10 M
GREAT
|
| Average 1W Daily Value |
0.12 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:42 |
| Symbol | BFRG |
| Name | BULLFROG AI HOLDINGS, INC. COMMON STOCK |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 18.54 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11.45 / 4,132.50 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 325 Ellington Boulevard, Gaithersburg, MD, United States, 20878
Phone: 240 658 6710
Website: https://www.bullfrogai.com
Description: Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Health Information ServicesAnalysed on the same criteria, ordered by market cap